• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Hyperprolactinemia: Effective Treatment With Aripiprazole

Hyperprolactinemia: Effective Treatment With Aripiprazole

May 21, 2021
Christina Guest, MD
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Christina Guest, MD Dr. Guest has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Zheng W et al, General Psychiatry 2019;32(5):e100091

Antipsychotic-induced hyperprolactinemia is a common adverse reaction contributing to treatment non-adherence. Male patients are embarrassed by the resulting breast enlargement, and female patients experience amenorrhea, infertility, and reduced bone density. We can bring prolactin levels down by decreasing the antipsychotic dose, switching to a different antipsychotic, or adding a dopamine agonist (eg, cabergoline), but these interventions put patients at risk of relapse.

Most antipsychotic medications cause hyperprolactinemia, though the risk is higher with first-generation agents and risperidone. Aripiprazole was the first antipsychotic approved with partial dopamine agonist activity, which may underlie its tendency to reduce, rather than raise, prolactin. Numerous case reports have found that adjunctive aripiprazole use reduces prolactin levels in antipsychotic-treated patients.

The authors conducted a meta-analysis of randomized controlled trials of patients with first-episode schizophrenia who received risperidone, olanzapine, or amisulpride (not approved as an antipsychotic in the US) with either adjunctive aripiprazole or placebo, and they compared patients’ serum prolactin levels. The final analysis included five randomized controlled trials with a total of 400 patients and a mean treatment duration of 11 weeks. A secondary outcome focused on improvement in psychosis as measured with the Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS). The mean dose of aripiprazole was 7.5 mg/day (range 2.5–10 mg/day) in the four studies that included dosage.

Prolactin levels in patients receiving aripiprazole in addition to an antipsychotic were significantly lower, with a mean difference of 50 ng/mL. An additional benefit was that patients taking adjunctive aripiprazole experienced significant improvement in PANSS negative symptoms, though not in positive symptoms. The rate of side effects, including extrapyramidal side effects (EPS), in the patients on adjunctive aripiprazole was no higher than in the patients receiving placebo.

CHPR’s Take
Addition of a small to moderate dose of aripiprazole significantly lowers prolactin levels in patients with antipsychotic-induced hyperprolactinemia, without contributing to side effects including EPS. An added benefit is that negative symptoms may improve with this intervention. It remains to be seen if other newer antipsychotics with partial agonism activity (eg, brexpiprazole, cariprazine, lumateperone) will show similar effects.
Hospital Psychiatry
KEYWORDS aripiprazole prolactin
    Christina Guest, MD

    More from this author
    www.thecarlatreport.com
    Issue Date: May 21, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Capacity Assessments, CHPR, April/May/June 2021
    Finally, Effective Treatments for Tardive Dyskinesia
    Decisional Capacity
    Capacity Assessment in Pregnant Patients
    Suvorexant May Prevent Delirium in Hospitalized Patients
    SSRIs and Intracerebral Hemorrhage Risk
    Can Antidepressants Prolong Survival in Cancer Patients?
    Hyperprolactinemia: Effective Treatment With Aripiprazole
    Note From the Editor-in-Chief
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.